{"id":11359,"date":"2026-05-27T01:01:00","date_gmt":"2026-05-26T23:01:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=7951345cc384a74b9f63aa654488268d"},"modified":"2026-05-27T01:01:00","modified_gmt":"2026-05-26T23:01:00","slug":"octave-bioscience-accelerates-precision-neurology-momentum-appoints-zachary-fernandes-as-vp-of-business-development-to-scale-strategic-partnerships","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=11359","title":{"rendered":"Octave Bioscience Accelerates Precision Neurology Momentum, Appoints Zachary Fernandes as VP of Business Development to Scale Strategic Partnerships"},"content":{"rendered":"

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker-driven solutions for multiple sclerosis, Parkinson's and other neurodegenerative diseases, today announced the appointment of Zachary Fernandes as Vice President, Business Development. He will lead Octave\u2019s partnership strategy focused on driving durable revenue growth through transformative, strategic collaborations across the life sciences ecosystem.<\/p><\/a><\/a>

\nMr. Fernandes has over 15 years of leadership experience in specialty diagnostics, with a proven track record, building strategic partnerships within public and private companies. Most recently as General Manager of Lucent Diagnostics at Quanterix Corporation, he led the formation of the business unit, driving adoption of a blood-based Alzheimer\u2019s test across provider practices and leading health systems. He led the recently announced strategic partnership with Tempus and Quanterix. As Vice President of Simoa Diagnostics, he successfully negotiated and implemented key In Vitro Diagnostic (IVD) partnerships across APAC markets, including Singapore, South Korea, and China.<\/p>

\nPreviously, Mr. Fernandes held senior business development roles at Mission Bio, Saphetor, and Veritas Genetics, where he launched and scaled the company\u2019s European business unit from inception to significant annual recurring revenue. His extensive deal-making experience spans partnerships with leading biopharma, specialty diagnostics and tools, national reference laboratories, reflecting his ability to drive high-value collaborations across the precision diagnostics landscape.<\/p>

\n\u201cZac joins us at a perfect inflection point. With our MSDA test already scaling through broad physician adoption and delivering biological insights to pharma partners, Zac\u2019s expertise will be vital as we launch our Parkinson\u2019s multi-analyte blood test later this year,\u201d said Doug Biehn, CEO of Octave Bioscience. \u201cHis unique success in developing category-leading precision neurology platforms and his entrepreneurship in forging transformative strategic partnerships globally makes him the ideal choice to advance our mission. We\u2019re thrilled to welcome him to Octave.\u201d<\/p>

\n\u201cI\u2019m excited to join Octave at such a significant inflection point for precision neurology,\u201d said Mr. Fernandes. \u201cThroughout my career in neurodegenerative disease diagnostics, I\u2019ve seen the impact that innovative, biomarker-driven solutions can have on patient care and clinical decision-making. Octave\u2019s validated platform and demonstrated clinical utility uniquely position the company to transform how MS and Parkinson\u2019s are diagnosed and managed. I look forward to forging new partnerships, expanding adoption, and helping accelerate access to these critical diagnostic tools for clinicians and patients worldwide.\u201d<\/p>

\nAbout Octave Bioscience, Inc.<\/b><\/p>

\nOctave Bioscience, Inc. is a commercial growth stage precision medicine company pioneering biomarker-driven solutions for neurodegenerative diseases, with an initial focus on Multiple Sclerosis, and Parkinson\u2019s Disease in partnership with the Michael J. Fox Foundation. Octave\u2019s comprehensive testing solutions provide objective, actionable insights to improve disease monitoring, treatment decisions, and patient outcomes. For more information, visit www.octavebio.com<\/a>.<\/p> Contacts<\/b>

\nMedia Contact<\/b>Caroline Corner\nICR Healthcare\ncaroline.corner@icrhealthcare.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

MENLO PARK, Calif.–(BUSINESS WIRE)–Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker-driven solutions for multiple sclerosis, Parkinson’s and other neurodegenerative diseases, today announced the appointment …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-11359","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11359"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11359\/revisions"}],"predecessor-version":[{"id":11360,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11359\/revisions\/11360"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}